RxLedger

Gammaked (Immune Globul G/Gly/IgA Avg 46) — Medicare Part D spending

Kedrion Biophar · Rank #207 by total Part D spend · CMS data year 2023

Medicare Part D spent $220,007,929 on Gammaked (Immune Globul G/Gly/IgA Avg 46) in 2023, the #207 drug by total Part D spending out of 3,598 drugs. That worked out to about $18.74 per dosage unit, $14,001 per claim and $142,032 per beneficiary, across 15,714 claims for 1,549 beneficiaries. Average spending per dosage unit rose +10.1% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

Gammaked (Immune Globul G/Gly/IgA Avg 46) spending at a glance (2023)

MetricGammaked (Immune Globul G/Gly/IgA Avg 46)
Total Part D spending (2023)$220,007,929
Total spending (2022)$173,634,924
Year-over-year change in total spending+26.7%
Average spending per dosage unit (2023)$18.74
Change in spend per dosage unit (YoY)+10.1%
Avg annual change per dosage unit (2019-2023 CAGR)+9.0%
Average spending per claim (2023)$14,001
Average spending per beneficiary (2023)$142,032
Total claims (2023)15,714
Beneficiaries (2023)1,549
Total dosage units (2023)11,697,400
Manufacturer(s)Kedrion Biophar
National rank by total spend (of 3,598 drugs)#207

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

2022 vs 2023

Gammaked (Immune Globul G/Gly/IgA Avg 46): year-over-year Medicare Part D figures. Per-claim/per-beneficiary "change" omitted because it mixes price and utilization. Source: CMS Medicare Part D Spending by Drug (data year 2023).
Metric20222023Change
Total spending$173,634,924$220,007,929+26.7%
Avg spend per dosage unit$17.03$18.74+10.1%
Avg spend per claim$13,835$14,001
Avg spend per beneficiary$127,205$142,032
Total claims12,55015,714
Beneficiaries1,3651,549

How Gammaked compares with nearby drugs

Drugs with total Part D spending closest to Gammaked (Immune Globul G/Gly/IgA Avg 46):

Gammaked (Immune Globul G/Gly/IgA Avg 46) and its nearest-spend peers. Source: CMS Medicare Part D Spending by Drug (data year 2023), data year 2023.
Drug (rank)Total spend 2023Per dosage unitPer-unit YoY
Gammaked (Immune Globul G/Gly/IgA Avg 46) (this drug, #207)$220,007,929$18.74+10.1%
Humalog Kwikpen U-200 (Insulin Lispro) (#205)$224,440,404$73.76+0.8%
Soliris (Eculizumab) (#206)$223,473,529$228.56+0.9%
Trazodone HCl (#208)$216,388,379$0.21+0.6%
Latanoprost (#209)$215,961,787$4.26-7.4%
Humalog Mix 75-25 Kwikpen (Insulin Lispro Protamin/Lispro) (#210)$213,875,690$36.40+0.5%

Frequently asked questions

How much does Medicare Part D spend on Gammaked?

Medicare Part D spent $220,007,929 on Gammaked (Immune Globul G/Gly/IgA Avg 46) in 2023 (the latest CMS data year), across 15,714 claims for 1,549 beneficiaries. That ranks #207 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.

What is the average spending per dosage unit for Gammaked?

In 2023, the weighted average Medicare Part D spending per dosage unit for Gammaked (Immune Globul G/Gly/IgA Avg 46) was $18.74. Compared with 2022 it rose +10.1%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.

Who makes Gammaked?

CMS attributes Gammaked (Immune Globul G/Gly/IgA Avg 46) to Kedrion Biophar in the 2023 Part D spending file. Average spending per claim was $14,001 and per beneficiary $142,032.

Is the Gammaked figure the price I pay?

No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.

Keep exploring

Source & what this means

Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.

Last updated: 2026-06-20